Neurocrine Biosciences | Efectivo Y Equivalentes



Cash And Equivalent Cambio Fecha
AbbVie USD 5.18B 349M 2025-03
Acadia Pharmaceuticals USD 762M 80.42M 2025-06
Agios Pharmaceuticals USD 80.87M 1.91M 2025-06
ALKERMES USD 521.2M 121.39M 2025-06
Alnylam Pharmaceuticals USD 1.11B 94.03M 2025-06
Amgen USD 8.03B 782M 2025-06
Biogen USD 2.76B 160.5M 2025-06
BioMarin Pharmaceutical USD 1.21B 601.78M 2025-06
Cytokinetics USD 74.94M 863.28M 2025-06
Dynavax Technologies USD 99.1M 562.24M 2025-06
Exelixis USD 164.43M 19.32M 2025-06
Gilead Sciences USD 5.14B 2.78B 2025-06
Halozyme Therapeutics USD 61.86M 114.47M 2025-06
Incyte USD 2.42B 13.08M 2025-06
Ionis Pharmaceuticals USD 297.3M 33.11M 2025-06
Neurocrine Biosciences USD 264M 69.9M 2025-06
Pfizer USD 1.64B 208M 2025-06
Prothena USD 471.39M 47.87M 2024-12
Regeneron Pharmaceuticals USD 2B 1.09B 2025-06
Repligen USD 708.86M 11.63M 2025-06
Sarepta Therapeutics USD 510.6M 269.73M 2025-06
Teva Pharmaceutical Industries USD 2.16B 464M 2025-06
Ultragenyx Pharmaceutical USD 166.11M 396.9M 2025-06
Vertex Pharmaceuticals USD 6.38B 1.71B 2025-06


Neurocrine Biosciences Efectivo Y Equivalentes - Los valores actuales, los datos históricos, las previsiones, estadísticas, gráficas y calendario económico - Aug 2025.